NCT05733611Phase 2Terminated

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Study sponsor: Replimune, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-08-18Actual
Enrollment · participants5Actual
Source updated2026-02-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Actual enrollment increased by 1 participants

Before: 4 participants (actual). After: 5 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 1 Jan 2027. After: 18 Aug 2025.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview